CN116033907A - 经由e-选择素靶向克服微环境介导的抗性的组合物和方法 - Google Patents

经由e-选择素靶向克服微环境介导的抗性的组合物和方法 Download PDF

Info

Publication number
CN116033907A
CN116033907A CN202180056345.7A CN202180056345A CN116033907A CN 116033907 A CN116033907 A CN 116033907A CN 202180056345 A CN202180056345 A CN 202180056345A CN 116033907 A CN116033907 A CN 116033907A
Authority
CN
China
Prior art keywords
subject
cancer
selectin
group
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180056345.7A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·L·麦格纳尼
威廉·E·福格勒
西奥多·史密斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crescent Biopharma Inc
Original Assignee
Glycomimetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomimetics Inc filed Critical Glycomimetics Inc
Publication of CN116033907A publication Critical patent/CN116033907A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202180056345.7A 2020-06-14 2021-06-11 经由e-选择素靶向克服微环境介导的抗性的组合物和方法 Pending CN116033907A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063038856P 2020-06-14 2020-06-14
US63/038,856 2020-06-14
US202063060605P 2020-08-03 2020-08-03
US63/060,605 2020-08-03
US202063198856P 2020-11-17 2020-11-17
US63/198,856 2020-11-17
PCT/US2021/036992 WO2021257398A1 (en) 2020-06-14 2021-06-11 Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting

Publications (1)

Publication Number Publication Date
CN116033907A true CN116033907A (zh) 2023-04-28

Family

ID=76731129

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180056345.7A Pending CN116033907A (zh) 2020-06-14 2021-06-11 经由e-选择素靶向克服微环境介导的抗性的组合物和方法

Country Status (12)

Country Link
US (1) US20230218649A1 (enExample)
EP (1) EP4164655A1 (enExample)
JP (1) JP2023529485A (enExample)
KR (1) KR20230024402A (enExample)
CN (1) CN116033907A (enExample)
AU (1) AU2021292458A1 (enExample)
BR (1) BR112022025480A2 (enExample)
CA (1) CA3181278A1 (enExample)
IL (1) IL298977A (enExample)
MX (1) MX2022015894A (enExample)
WO (1) WO2021257398A1 (enExample)
ZA (1) ZA202213322B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250100273A (ko) * 2023-12-26 2025-07-03 서울대학교병원 난소암 예방 또는 치료를 위한 데시타빈 및 벨로테칸의 병용 요법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013096926A1 (en) * 2011-12-22 2013-06-27 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
WO2019173229A1 (en) * 2018-03-05 2019-09-12 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2264043T3 (pl) 2005-09-02 2018-04-30 Glycomimetics, Inc. Heterobifunkcyjne inhibitory pan-selektyny
WO2009073911A1 (en) 2007-12-10 2009-06-18 Mater Medical Research Institute Treatment and prophylaxis
CA2760292A1 (en) 2009-05-01 2010-11-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
WO2015048616A1 (en) * 2013-09-30 2015-04-02 Glycomimetics, Inc. Methods and compositions for treating and/or preventing mucositis
JP6689854B2 (ja) 2014-12-03 2020-04-28 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤
US20200171005A9 (en) 2015-12-02 2020-06-04 Glycomimetics, Inc. Heterobifunctional Pan-Selectin Antagonists Having a Triazole Linker
AU2017341065B2 (en) 2016-10-07 2023-04-06 Crescent Biopharma, Inc. Highly potent multimeric E-selectin antagonists
JP7275131B2 (ja) * 2017-11-30 2023-05-17 グリコミメティクス， インコーポレイテッド 骨髄浸潤リンパ球を動員する方法、およびその使用
KR20200104889A (ko) 2017-12-29 2020-09-04 글리코미메틱스, 인크. E-셀렉틴 및 갈렉틴-3의 이종이기능성 억제제
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
WO2020219419A1 (en) 2019-04-24 2020-10-29 Glycomimetics, Inc. Multimeric pan–selectin antagonists
JP2022529806A (ja) 2019-04-24 2022-06-24 グリコミメティクス， インコーポレイテッド Ｅ－セレクチン、ガレクチン－３、および／またはｃｘｃｒ４ケモカイン受容体のガラクトース連結型多量体糖模倣性阻害剤
US20220265691A1 (en) 2019-07-12 2022-08-25 Glycomimetics, Inc. Methods for use of gene expression as an indicator of e-selectin inhibitor efficacy and clinical outcome for multiple tumor types

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013096926A1 (en) * 2011-12-22 2013-06-27 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
CN104039805A (zh) * 2011-12-22 2014-09-10 糖模拟物有限公司 E-选择蛋白拮抗剂化合物、组合物及使用方法
WO2019173229A1 (en) * 2018-03-05 2019-09-12 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BHATT VIJAYA RAJ: "Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling", CANCER TREATMENT REVIEWS, vol. 75, no. 2019, 31 December 2019 (2019-12-31), pages 52 - 61, XP085668071, DOI: 10.1016/j.ctrv.2019.04.001 *
FOGLER WILLIAM E ET AL: "Glycomimetic Antagonist of E-Selectin, GMI-1271, Enhances Therapeutic Activity of the Hypomethylating Agent, 5-Azacitidine, in the KG1 Model of AML", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, vol. 130, 8 December 2017 (2017-12-08), pages 5065, XP086629182, DOI: 10.1182/blood.V130.Suppl_1.5065.5065 *

Also Published As

Publication number Publication date
WO2021257398A1 (en) 2021-12-23
CA3181278A1 (en) 2021-12-23
EP4164655A1 (en) 2023-04-19
BR112022025480A2 (pt) 2023-01-17
MX2022015894A (es) 2023-01-24
ZA202213322B (en) 2024-04-24
KR20230024402A (ko) 2023-02-20
AU2021292458A1 (en) 2023-01-19
US20230218649A1 (en) 2023-07-13
IL298977A (en) 2023-02-01
JP2023529485A (ja) 2023-07-10

Similar Documents

Publication Publication Date Title
Fu et al. Tumor-associated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma
Mueller et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer
KR20250053841A (ko) 암의 치료 및/또는 예방을 위한 의약품
KR20200024823A (ko) 급성 골수성 백혈병(acute myeloid leukaemia) 치료를 위한 항 cd70-항체 argx-110의 용도
CN105873440A (zh) 适用于治疗癌症的用于抑制tie2激酶的方法
Paesler et al. Targeting the vascular endothelial growth factor in hematologic malignancies
WO2022270524A1 (ja) 癌の治療及び／又は予防のための医薬品
CN116033907A (zh) 经由e-选择素靶向克服微环境介导的抗性的组合物和方法
Deng et al. Narciclasine induces colon carcinoma cell apoptosis by inhibiting the IL-17A/Act1/TRAF6/NF-κB signaling pathway
AU2012316266B2 (en) Combination therapy for chemoresistant cancers
US20240269157A1 (en) Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting
TWI753178B (zh) Mcl-1抑制劑與血液癌症標準療法之組合，其用途及醫藥組合物
KR20220044679A (ko) 항ccr4 항체 저항성의 암 치료제
JP2023527411A (ja) がん細胞の負荷を減少させ、正常な造血を保護するための化合物および方法
KR20240041917A (ko) 암의 치료 및/또는 예방을 위한 의약품
KR20230044452A (ko) 암을 치료하기 위한 bcl-2 억제제 및 저메틸화제의 조합물, 이의 용도 및 약학적 조성물
KR102558989B1 (ko) 항암 화학요법으로 인한 내성을 완화하고 항암 화학요법의 효과를 증진시키기 위한 약학적 조성물 및 그 용도
KR20250054778A (ko) 암의 치료 및/또는 예방을 위한 의약품
RU2429848C2 (ru) Композиции для лечения системного мастоцитоза
WO2012037553A2 (en) Use of pkc-iota inhibitors for the treatment of breast cancer
KR20250052364A (ko) 암의 치료 및/또는 예방을 위한 의약품
KR20250052368A (ko) 암의 치료 및/또는 예방을 위한 의약품
JP2022023033A (ja) ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
Podolski et al. INFLUENCE OF TREATMENT WITH AREDIA (PAMIDRO-NAT ON THE SKELETAL METASTASES FROM BREAST CANCER
BEDSIDE Presidential Symposium

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230428